Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia

Druker, Brian; Talpaz, Moshe; Resta, Debra; Peng, Bin; Buchdunger, Elisabeth; Ford, J.; Lydon, Nicholas; M. Kantarjian, Hagop; Capdeville, Renaud; Ohno-Jones, Sayuri; L. Sawyers, Charles

doi:10.1056/nejm200104053441401

Public

Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia

Published in New England Journal of Medicine • Apr 5, 2001

Authors:

Brian Druker

Moshe Talpaz

Debra Resta

Abstract

BACKGROUND: BCR-ABL is a constitutively activated tyrosine kinase that causes chronic myeloid leukemia (CML). Since tyrosine kinase activity is essential to the transforming function of BCR-ABL, an inhibitor of the kinase could be an effective treatment for CML. METHODS: We conducted a phase 1, dose...

Subject

Myeloid leukemia

Tyrosine kinase

CD135

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!